
Excited to share our new @biorxivpreprint! We developed antibody-lectin (AbLec) chimeras as a modular molecular architecture to target sugars, or glycans, for cancer immunotherapy. 1/n tinyurl.com/5yw69eeu #glycotime @CarolynBertozzi @Stanford_ChEMH @StanfordUChem @HHMINEWS


















